Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤¾Ï ȯÀÚ¿¡¼­ Lewis X Ç×ü¸¦ ÀÌ¿ëÇÑ ¸é¿ª¼¼Æ÷°Ë»çÀÇ ÀÇÀÇ Immunocytology of the Lewis X Antigen in Patients with Bladder Tumor

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 3È£ p.327 ~ 331
¼Ò¼Ó »ó¼¼Á¤º¸
³²¿õö/Ung Chul Nam À̼±ÁÖ/ÀÓ¼ºÁ÷/ÀÌÁÖÈñ/±èÁøÀÏ/Sun Ju Lee/Sung Jig Lim/Ju Hie Lee/Jin Il Kim

Abstract

¼­·Ð
¹æ±¤¾Ï ȯÀÚÀÇ Ä¡·á¿¡ ÀÖ¾î ¹æ±¤¾ÏÀÇ Á¶±â Áø´ÜÀ̳ª ¼ö¼ú ÈÄ Àç¹ß°ú º´±â »ó½ÂÀÌ È¯ÀÚÀÇ
¿¹ÈÄ¿Í »îÀÇ Áú¿¡ ¹ÌÄ¡´Â ¿µÇâÀº Áö´ëÇÏ´Ù°í ÇÒ ¼ö ÀÖ´Ù. ¹æ±¤¾ÏÀÇ Æ¯Â¡Àº ù Áø´Ü ÈÄ ¾à
50-70%ÀÇ È¯ÀÚ°¡ Ä¡·á ÀÌÈÄ¿¡µµ Àç¹ßÀ» ÇÑ´Ù´Â Á¡ÀÌ´Ù. ¹æ±¤¾ÏÀÇ Áø´Ü ¹× ÃßÀû°Ë»ç´Â ¿ä¼¼
Æ÷°Ë»ç¿Í ¹æ±¤°æ°Ë»ç°¡ Å« ºñÁßÀ» Â÷ÁöÇÏ°í ÀÖÀ¸³ª ¿ä¼¼Æ÷°Ë»ç´Â ÇöÀç±îÁö 30-50% Á¤µµÀÇ
¹Î°¨µµ¿Í 80-90%ÀÇ Æ¯À̵µ¸¦ °¡Áö¸ç ÀúºÐÈ­µµ ÀÌÇà»óÇǼ¼Æ÷¾ÏÀÇ ¾ç¼º¹Î°¨µµ´Â 0-55%·Î ³·
Àº °ÍÀÌ ´ÜÁ¡À̶ó°í ÇÒ ¼ö ÀÖ´Ù. ¹æ±¤°æ°Ë»ç´Â ȯÀÚ¿¡°Ô ħ½ÀÀûÀÌ°í À°¾ÈÀûÀÎ º´º¯¸¸ ¹àÇô
³¾ ¼ö ÀÖ´Ù´Â °ÍÀÌ ´ÜÁ¡ÀÌ´Ù.
ÃÖ±Ù¿¡´Â ºÐÀÚ»ý¹°ÇÐÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¹æ±¤¾Ï ȯÀÚÀÇ ¿ä¿¡¼­ ¹æ±¤¾ÏÀÇ ¿©ºÎ¸¦ È®ÀÎÇÏ´Â
»õ·Î¿î °Ë»ç¹ýµéÀÌ ÀÓ»ó¿¡¼­ ¿¬±¸µÇ°í ÀÖÀ¸¸ç ¿äÁß NMP22 ÃøÁ¤¹ý, BTA°Ë»ç¹ý, telomorase
°Ë»ç¹ý, DNA cytometry, ¸é¿ª¼¼Æ÷°Ë»ç, Á¤·®Àû ±¤ÇÐÇö¹Ì°æ°Ë»ç, interphase cytogenetics µî
ÀÌ ÀÖ´Ù. Lewis XÇ×ü´Â Lewis°è Ç×üÀÇ ÀÏÁ¾À¸·Î ¼¼Æ÷ Ç¥¸é¿¡ ºÎÂøµÇ¾î Àִ ǥ¸éÇ×ü·Î
¸é¿ª°áÁ¤ºÎÀ§ÀÇ ±¸Á¶´Â trisaccharide galactose B 1-4(frucose 1-3) N-acetylglucosamineÀ¸
·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç ½ÅÀåÀÇ ±ÙÀ§¼¼´¢°ü ¼¼Æ÷¿Í ¼Ò¼öÀÇ ¼ÒÈ­±â»óÇǼ¼Æ÷, °ú¸³±¸ ¹× žÆÀÇ ¹æ
±¤ÀÌÇà»óÇǼ¼Æ÷¿¡¼­ ¹ßÇöµÇ³ª ¼ºÀÎÀÇ Á¤»ó ¹æ±¤ÀÌÇà»óÇÇ ¼¼Æ÷¿¡¼­´Â ¹ßÇöµÇÁö ¾Ê´Â´Ù. ±×¸®
°í ¹æ±¤ÀÇ À¯µÎÁ¾°ú ÀÌÇà»óÇǼ¼Æ÷¾Ï¿¡¼­ º´±â¿Í ºÐÈ­µµ¿¡ °ü°è¾øÀÌ ¾ç¼ºÀ¸·Î ³ªÅ¸³ª¸ç Ç÷¾×
Çü°ú ¹«°üÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ¿¡ ÀúÀÚµéÀº ¹æ±¤°æ°Ë»ç ÈÄ ¹æ±¤¾ÏÀ¸·Î Áø´ÜµÈ 36¸íÀÇ
ȯÀÚÀÇ ¼¼Ã´´¢¿¡¼­ Lowis X ¸é¿ª¼¼Æ÷°Ë»ç¸¦ ½ÃÇàÇÏ¿© Lewis X ¸é¿ª¼¼Æ÷°Ë»çÀÇ ¹Î°¨µµ¸¦
Á¶»çÇÏ¿´À¸¸ç, ¿ä¼¼Æ÷°Ë»çÀÇ ¹Î°¨µµ¿Í ºñ±³ÇÏ¿© ±× À¯¿ë¼ºÀ» ¿¬±¸ÇÏ¿´´Ù.

Purpose: To improve low sensitivity of urinary cytology in diagnosis and surveillance
of bladder cancer, we performed a study using the Lewis X immunocytology with the
murine BG-7 monoclonal anti-Lewis X immunoglobulin M antibody while comparing it
with conventional urinary cytology.
Materials and Methods: Barbotage bladder washings were performed in 36 patients
who were diagnosed as having bladder tumor after cystoscopy. The specimens were
divided into conventional urinary cytology and immunocytochemical examinations. The
cytologic examination was done according to Papanicolau. Indirect immunoperoxidase
staining of urine samples was done using the murine BG-7 monoclonal antibody against
the Lewis X antigen. Biopsies were obtained in all cases via transurethral resection. The
results were analysed according to the tumor stage and grade.
Results: Of the 36 patients, 33 patients were diagnosed with transitional cell
carcinoma, 1 with inverted papilloma, and 2 with chronic inflammation. Immunocytology
showed positive results in 25 of the 33 patients, corresponding to a sensitivity of 75.8%
while conventional cytology showed a sensitivity of 45.5%. This discrepancy was vivid
in the cases of low grade transitional cell carcinoma. The sensitivities of conventional
cytology were 23% in grade ¥° and 50% in grade ¥±, while those of immunocytology
were 50% in grade ¥° and 100% in grade ¥±.
Conclusions: Our data show that Lewis X immunocytology using the murine BG-7
monoclonal anti-Lewis X antibody can improve the sensitivity of noninvasive detection
of transitional cell carcinoma of the bladder, especially in low grade tumor.

Å°¿öµå

Bladder tumor; Lewis X antigen; Cytology;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS